de Sanctis L, Giachero F, Mantovani G, Weber G, Salerno M, Baroncelli G I, Elli M F, Matarazzo P, Wasniewska M, Mazzanti L, Scirè G, Tessaris D
Department of Public Health and Pediatric Sciences, University of Turin - Regina Margherita Children's Hospital - Health and Science City, Subintensiva Allargata Prima Infanzia, Piazza Polonia 94, 10126, Torino, Italy.
Kinderklinik, Evangelisches Krankenhaus Oberhausen, Oberhausen, Germany.
Ital J Pediatr. 2016 Nov 21;42(1):101. doi: 10.1186/s13052-016-0310-3.
Genetic and epigenetic alterations in the GNAS locus are responsible for the Gsα protein dysfunctions causing Pseudohypoparathyroidism (PHP) type Ia/c and Ib, respectively. For these heterogeneous diseases characterized by multiple hormone resistances and Albright's Hereditary Osteodystrophy (AHO) the current classification results inadequate because of the clinical overlap between molecular subtypes and a standard clinical approach is still missing. In the present paper several members of the Study Group Endocrine diseases due to altered function of Gsα protein of the Italian Society of Pediatric Endocrinology and Diabetology (ISPED) have reviewed and updated the clinical-molecular data of the largest case series of (epi)/genetically characterized AHO/PHP patients; they then produced a common healthcare pathway for patients with these disorders.
The molecular analysis of the GNAS gene and locus identified the causal alteration in 74 subjects (46 genetic and 28 epigenetic mutations). The clinical data at the diagnosis and their evolution during up to 15 years follow-up were collected using two different cards.
In patients with genetic mutations the growth impairment worsen during the time, while obesity prevalence decreases; subcutaneous ossifications seem specific for this group. Brachydactyly has been detected in half of the subjects with epigenetic alterations, in which the disease overts later in life, often with symptomatic hypocalcaemia, and also early TSH and GHRH resistances have been recorded.
A dedicated healthcare pathway addressing all these aspects in a systematic way would improve the clinical management, allowing an earlier recognition of some PHP features, the optimization of their medical treatment and a better clinical-oriented molecular analysis. Furthermore, standardized follow-up data would provide new insight into less known aspects.
GNAS基因座的遗传和表观遗传改变分别导致了Gsα蛋白功能障碍,从而引起Ia/c型和Ib型假性甲状旁腺功能减退症(PHP)。对于这些以多种激素抵抗和奥尔布赖特遗传性骨营养不良(AHO)为特征的异质性疾病,目前的分类并不充分,因为分子亚型之间存在临床重叠,且仍缺乏标准的临床方法。在本文中,意大利儿科学会和糖尿病学会(ISPED)Gsα蛋白功能改变所致内分泌疾病研究组的几位成员回顾并更新了最大系列的(表观)基因特征明确的AHO/PHP患者的临床分子数据;然后他们为患有这些疾病的患者制定了一条通用的医疗途径。
对GNAS基因和基因座进行分子分析,在74名受试者中确定了致病改变(46个基因和28个表观遗传突变)。使用两张不同的卡片收集诊断时的临床数据及其在长达15年随访期间的演变情况。
在基因突变患者中,生长发育障碍随时间加重,而肥胖患病率降低;皮下骨化似乎是该组特有的。在一半的表观遗传改变受试者中检测到短指畸形,这些患者发病较晚,常伴有症状性低钙血症,并且还记录到早期促甲状腺激素和生长激素释放激素抵抗。
一条系统解决所有这些方面问题的专门医疗途径将改善临床管理,使一些PHP特征能更早被识别,优化其药物治疗,并进行更好的以临床为导向的分子分析。此外,标准化的随访数据将为鲜为人知的方面提供新的见解。